Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients - Results of the RESPECT-Study

Sadeleştirilmiş öğe sayfası
dc.contributor.authorWeniger, Maximilian
dc.contributor.authorMoir, John
dc.contributor.authorDamm, Marko
dc.contributor.authorMaggino, Laura
dc.contributor.authorKordes, Maximilian
dc.contributor.authorRosendahl, Jonas
dc.contributor.authorCeyhan, Gueralp O.
dc.contributor.authorSchorn, Stephan
dc.contributor.authorRESPECT\\-Study Grp
dc.date.accessioned2025-10-16T15:20:17Z
dc.date.issued2020
dc.identifier.doi10.1016/j.suronc.2020.08.031
dc.identifier.otherWOS:000600199100021
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/7495
dc.publisherELSEVIER SCI LTD
dc.sourceSURGICAL ONCOLOGY-OXFORD
dc.subjectNeoadjuvant chemotherapy
dc.subjectSurvival
dc.subjectAdvanced age
dc.titleNeoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients - Results of the RESPECT-Study
dc.typeArticle

Dosyalar

Koleksiyonlar

WOS